ZA200604491B - Process for the preparation of thiazolopyrimidines - Google Patents
Process for the preparation of thiazolopyrimidines Download PDFInfo
- Publication number
- ZA200604491B ZA200604491B ZA200604491A ZA200604491A ZA200604491B ZA 200604491 B ZA200604491 B ZA 200604491B ZA 200604491 A ZA200604491 A ZA 200604491A ZA 200604491 A ZA200604491 A ZA 200604491A ZA 200604491 B ZA200604491 B ZA 200604491B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- compound
- optionally substituted
- group
- independently selected
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 23
- 238000002360 preparation method Methods 0.000 title claims description 10
- 150000008634 thiazolopyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 67
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- -1 hydroxy, amino Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 9
- DCSLKYLPOSSKFY-UHFFFAOYSA-N 3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1=NC=C2SC(=O)NC2=N1 DCSLKYLPOSSKFY-UHFFFAOYSA-N 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- MBKZGLGIFLDKOD-UHFFFAOYSA-N [N].C1=CSC=N1 Chemical group [N].C1=CSC=N1 MBKZGLGIFLDKOD-UHFFFAOYSA-N 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- JRTCCNKNXFGGJT-UHFFFAOYSA-N 5-[(2,3-difluorophenyl)methylsulfanyl]-7-[(1,3-dihydroxy-2-methylpropan-2-yl)amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound N=1C=2NC(=O)SC=2C(NC(CO)(CO)C)=NC=1SCC1=CC=CC(F)=C1F JRTCCNKNXFGGJT-UHFFFAOYSA-N 0.000 claims 1
- 101710198144 Endopolygalacturonase I Proteins 0.000 claims 1
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 claims 1
- 101710191566 Probable endopolygalacturonase I Proteins 0.000 claims 1
- 238000001783 near-resonance Rayleigh scattering spectroscopy Methods 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- UJTPZISIAWDGFF-UHFFFAOYSA-N ethenylsulfonylbenzene Chemical group C=CS(=O)(=O)C1=CC=CC=C1 UJTPZISIAWDGFF-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
- MNOALXGAYUJNKX-UHFFFAOYSA-N s-chloro chloromethanethioate Chemical compound ClSC(Cl)=O MNOALXGAYUJNKX-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 1
- FTBSGSZZESQDBM-UHFFFAOYSA-N 1-(bromomethyl)-2,3-difluorobenzene Chemical compound FC1=CC=CC(CBr)=C1F FTBSGSZZESQDBM-UHFFFAOYSA-N 0.000 description 1
- HGTTYFKDCTYIIZ-UHFFFAOYSA-N 2,2,5-trimethyl-1,3-dioxan-5-amine Chemical compound CC1(N)COC(C)(C)OC1 HGTTYFKDCTYIIZ-UHFFFAOYSA-N 0.000 description 1
- YKKLUGZUKGHPJP-UHFFFAOYSA-N 2,2-dimethylpropanoyloxymethyl 4-chloro-2,2-dimethylbutanoate Chemical compound ClCCC(C(=O)OCOC(C(C)(C)C)=O)(C)C YKKLUGZUKGHPJP-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- BWYGMIYEADAIGW-UHFFFAOYSA-N 6-amino-2-sulfanylidene-1h-pyrimidin-4-one;hydrate Chemical compound O.NC1=CC(=O)NC(=S)N1 BWYGMIYEADAIGW-UHFFFAOYSA-N 0.000 description 1
- CMXFFNQBVIOLNG-UHFFFAOYSA-N 7-chloro-5-[(2,3-difluorophenyl)methylsulfanyl]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound FC1=CC=CC(CSC=2N=C3NC(=O)SC3=C(Cl)N=2)=C1F CMXFFNQBVIOLNG-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- GLYOPNLBKCBTMI-UHFFFAOYSA-N [2-chloro-2-(1-chloro-2-phenylethoxy)ethyl]benzene Chemical compound C=1C=CC=CC=1CC(Cl)OC(Cl)CC1=CC=CC=C1 GLYOPNLBKCBTMI-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0328243.1A GB0328243D0 (en) | 2003-12-05 | 2003-12-05 | Methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200604491B true ZA200604491B (en) | 2007-10-31 |
Family
ID=29764654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604491A ZA200604491B (en) | 2003-12-05 | 2006-06-01 | Process for the preparation of thiazolopyrimidines |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7790883B2 (enExample) |
| EP (1) | EP1711505B1 (enExample) |
| JP (1) | JP4808629B2 (enExample) |
| KR (1) | KR101170188B1 (enExample) |
| CN (1) | CN1914213B (enExample) |
| AR (1) | AR046750A1 (enExample) |
| AT (1) | ATE471941T1 (enExample) |
| AU (1) | AU2004296241B2 (enExample) |
| BR (1) | BRPI0417300A (enExample) |
| CA (1) | CA2546719A1 (enExample) |
| DE (1) | DE602004027840D1 (enExample) |
| ES (1) | ES2345660T3 (enExample) |
| GB (1) | GB0328243D0 (enExample) |
| IL (1) | IL175743A (enExample) |
| MY (1) | MY143761A (enExample) |
| NO (1) | NO20063111L (enExample) |
| NZ (2) | NZ583012A (enExample) |
| SG (1) | SG149005A1 (enExample) |
| TW (1) | TWI347945B (enExample) |
| UY (1) | UY28651A1 (enExample) |
| WO (1) | WO2005056563A2 (enExample) |
| ZA (1) | ZA200604491B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| JP6463366B2 (ja) | 2013-10-10 | 2019-01-30 | イースタン バージニア メディカル スクール | １２−リポキシゲナーゼ阻害物質としての４−（（２−ヒドロキシ−３−メトキシベンジル）アミノ）ベンゼンスルホンアミド誘導体 |
| GB201807898D0 (en) * | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2924472A (en) * | 1957-06-27 | 1960-02-09 | Gen Motors Corp | Pipe joint seal |
| GB1009477A (en) | 1962-02-13 | 1965-11-10 | Smith Kline French Lab | Novel process for preparing heterocyclic compounds |
| US3182062A (en) * | 1962-02-28 | 1965-05-04 | Smith Kline French Lab | Synthesis of quinoxalines and analogues thereof |
| US3318900A (en) * | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
| BE668603A (enExample) * | 1964-08-20 | |||
| DE2331223C2 (de) | 1972-06-19 | 1984-11-22 | Kohjin Co., Ltd., Tokio / Tokyo | S-substituierte-2-Thioadenosine, deren 5'-Monophosphate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten |
| JPS5188994A (en) | 1975-02-04 | 1976-08-04 | Shinkijichikan 88 aminoadeninjudotainoseizoho | |
| US4120521A (en) * | 1975-08-28 | 1978-10-17 | Rieber & Son Plastic-Industri A/S | Combined mould element and sealing ring |
| EG12406A (en) * | 1976-08-12 | 1979-03-31 | Janssen Pharmaceutica Nv | Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides |
| GB1600293A (en) * | 1977-02-04 | 1981-10-14 | British Oceanics Ltd | Sealing arrangements |
| US4188040A (en) * | 1977-04-06 | 1980-02-12 | Firma WOCO Franz-Josef Wolf & Co. | Sealing ring |
| DE2726959A1 (de) * | 1977-06-15 | 1979-01-18 | Arlt Christian | Dichteinsatz zum dichten verbinden von zwei rohren |
| FR2421899A1 (fr) * | 1978-01-16 | 1979-11-02 | Roussel Uclaf | Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits |
| US4410528A (en) * | 1980-05-16 | 1983-10-18 | Kyowa Hakko Kogyo Co., Ltd. | Hypotensive piperidine derivatives |
| DE3219522A1 (de) * | 1981-10-28 | 1983-12-01 | Denso-Chemie Wedekind Kg, 5090 Leverkusen | Steckmuffendichtung fuer rohre |
| FR2547888B1 (fr) * | 1983-06-22 | 1985-12-13 | Sabla Sa | Bague d'etancheite a implants pour tuyaux a emboitement |
| CA1338012C (en) | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
| SE8800348L (sv) * | 1988-02-03 | 1989-08-04 | Forsheda Ab | Taetningsring och verktyg foer framstaellning daerav |
| FR2659656B1 (fr) | 1990-03-15 | 1994-09-09 | Sanofi Sa | Derives de pyrimidinedione-2,4 et medicaments les contenant. |
| DE4119767A1 (de) | 1991-06-15 | 1992-12-17 | Dresden Arzneimittel | Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten |
| US5169161A (en) * | 1991-09-19 | 1992-12-08 | Hail Mary Rubber Co., Inc. | Symmetrical gasket for pipe joints |
| DE4134089C2 (de) * | 1991-10-15 | 1994-10-13 | Dueker Eisenwerk | Schubgesicherte Muffenverbindung |
| DE4229609C2 (de) * | 1992-09-04 | 2003-05-08 | Forsheda Stefa Gmbh | Abdichtung zwischen zwei ineinandersteckbaren Teilen |
| US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| EP0778277B1 (en) | 1995-12-08 | 2003-06-25 | Pfizer Inc. | Substituted heterocyclic derivatives as CRF antagonists |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SE515033C2 (sv) * | 1995-12-27 | 2001-06-05 | Forsheda Ab | Tätningsanordning |
| PL194689B1 (pl) | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
| EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
| WO1997040035A1 (en) | 1996-04-19 | 1997-10-30 | Neurosearch A/S | 1-(4-piperidyl)-benzimidazoles having neurotrophic activity |
| BR9711970A (pt) | 1996-08-28 | 1999-08-24 | Pfizer | Derivados 6,5-substitu¡do-heterobic¡clicos |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| JP2002510327A (ja) | 1997-07-25 | 2002-04-02 | メルク エンド カンパニー インコーポレーテッド | 環状アミンケモカイン受容体活性調節剤 |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| KR100613634B1 (ko) * | 1997-11-28 | 2006-08-18 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규한 복소환 화합물 |
| DK1049689T3 (da) | 1998-01-19 | 2002-07-22 | Pfizer | 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister |
| CN1166665C (zh) * | 1998-03-19 | 2004-09-15 | 日本农药株式会社 | 芳基哌啶衍生物及其用途 |
| WO1999051608A1 (en) | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| MA26659A1 (fr) | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
| SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| US5988695A (en) * | 1998-08-26 | 1999-11-23 | S&B Technical Products, Inc. | Pipe gasket with embedded ring |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| AU770551B2 (en) | 1998-12-28 | 2004-02-26 | 4-Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| WO2000045800A2 (en) | 1999-02-02 | 2000-08-10 | K.U. Leuven Research & Development | Immunosurpressive effects of pteridine derivatives |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6142484A (en) * | 1999-04-15 | 2000-11-07 | Vassallo Research & Development Corporation | Composite multi-pressure gasket |
| US6432981B1 (en) * | 1999-06-11 | 2002-08-13 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| CA2393896A1 (en) | 1999-09-15 | 2001-03-22 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| PE20010628A1 (es) | 1999-10-01 | 2001-06-18 | Takeda Chemical Industries Ltd | Compuestos de amina ciclica, su produccion y su uso |
| EP1122257B1 (en) | 2000-01-05 | 2005-10-12 | Pfizer Inc. | Benzimidazole compounds as ORL1-receptor agonists |
| GB2359078A (en) * | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359081A (en) * | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359079A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| DE60101372T2 (de) | 2000-02-11 | 2004-10-14 | Astrazeneca Ab | Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität |
| GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| AU4274401A (en) * | 2000-03-24 | 2001-10-03 | Meiji Seika Kaisha | Diphenylalkylamine derivatives useful as opioid delta receptor agonists |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
| WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| SE0003828D0 (sv) * | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| SE0004110L (sv) * | 2000-11-10 | 2002-05-11 | Forsheda Ab | Tätningsring |
| SE0101322D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
| GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221828D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| JP2007507494A (ja) | 2003-10-07 | 2007-03-29 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| WO2006064228A2 (en) | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | Thiazolopyramidine compounds for the modulation of chemokine receptor activity |
-
2003
- 2003-12-05 GB GBGB0328243.1A patent/GB0328243D0/en not_active Ceased
-
2004
- 2004-11-25 TW TW093136325A patent/TWI347945B/zh not_active IP Right Cessation
- 2004-12-02 NZ NZ583012A patent/NZ583012A/en unknown
- 2004-12-02 AU AU2004296241A patent/AU2004296241B2/en not_active Ceased
- 2004-12-02 NZ NZ547685A patent/NZ547685A/en not_active IP Right Cessation
- 2004-12-02 KR KR1020067010850A patent/KR101170188B1/ko not_active Expired - Fee Related
- 2004-12-02 SG SG200809048-2A patent/SG149005A1/en unknown
- 2004-12-02 US US10/581,143 patent/US7790883B2/en not_active Expired - Fee Related
- 2004-12-02 BR BRPI0417300-7A patent/BRPI0417300A/pt not_active IP Right Cessation
- 2004-12-02 CN CN2004800414459A patent/CN1914213B/zh not_active Expired - Fee Related
- 2004-12-02 ES ES04801262T patent/ES2345660T3/es not_active Expired - Lifetime
- 2004-12-02 DE DE602004027840T patent/DE602004027840D1/de not_active Expired - Lifetime
- 2004-12-02 MY MYPI20044990A patent/MY143761A/en unknown
- 2004-12-02 AT AT04801262T patent/ATE471941T1/de not_active IP Right Cessation
- 2004-12-02 EP EP04801262A patent/EP1711505B1/en not_active Expired - Lifetime
- 2004-12-02 WO PCT/GB2004/005072 patent/WO2005056563A2/en not_active Ceased
- 2004-12-02 CA CA002546719A patent/CA2546719A1/en not_active Abandoned
- 2004-12-02 JP JP2006542009A patent/JP4808629B2/ja not_active Expired - Fee Related
- 2004-12-03 UY UY28651A patent/UY28651A1/es not_active Application Discontinuation
- 2004-12-03 AR ARP040104522A patent/AR046750A1/es active IP Right Grant
-
2006
- 2006-05-18 IL IL175743A patent/IL175743A/en not_active IP Right Cessation
- 2006-06-01 ZA ZA200604491A patent/ZA200604491B/en unknown
- 2006-07-04 NO NO20063111A patent/NO20063111L/no not_active Application Discontinuation
-
2008
- 2008-05-15 US US12/121,228 patent/US20090043097A1/en not_active Abandoned
-
2009
- 2009-12-15 US US12/638,415 patent/US20100217000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE471941T1 (de) | 2010-07-15 |
| US20090043097A1 (en) | 2009-02-12 |
| BRPI0417300A (pt) | 2007-03-06 |
| EP1711505A2 (en) | 2006-10-18 |
| EP1711505B1 (en) | 2010-06-23 |
| IL175743A (en) | 2011-10-31 |
| KR101170188B1 (ko) | 2012-07-31 |
| ES2345660T3 (es) | 2010-09-29 |
| JP2007513131A (ja) | 2007-05-24 |
| CN1914213B (zh) | 2011-05-11 |
| CA2546719A1 (en) | 2005-06-23 |
| NZ547685A (en) | 2010-02-26 |
| GB0328243D0 (en) | 2004-01-07 |
| TW200524945A (en) | 2005-08-01 |
| AR046750A1 (es) | 2005-12-21 |
| CN1914213A (zh) | 2007-02-14 |
| US20070282103A1 (en) | 2007-12-06 |
| NO20063111L (no) | 2006-09-05 |
| US20100217000A1 (en) | 2010-08-26 |
| US7790883B2 (en) | 2010-09-07 |
| WO2005056563A3 (en) | 2005-08-25 |
| WO2005056563A2 (en) | 2005-06-23 |
| AU2004296241A1 (en) | 2005-06-23 |
| SG149005A1 (en) | 2009-01-29 |
| KR20060118525A (ko) | 2006-11-23 |
| MY143761A (en) | 2011-07-15 |
| TWI347945B (en) | 2011-09-01 |
| DE602004027840D1 (de) | 2010-08-05 |
| NZ583012A (en) | 2011-08-26 |
| UY28651A1 (es) | 2005-07-29 |
| AU2004296241B2 (en) | 2009-01-22 |
| JP4808629B2 (ja) | 2011-11-02 |
| IL175743A0 (en) | 2006-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2379553B1 (en) | Bicyclic compounds for the reduction of beta-amyloid production | |
| US20100217000A1 (en) | Process for the Preparation of Thiazolopyrimidines | |
| WO2011009898A1 (en) | Fused aminodihydro-oxazine derivatives | |
| US10000497B2 (en) | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | |
| EP2007377A2 (en) | Antibacterial agents | |
| RU2733400C2 (ru) | Производные пиразолопиридина в качестве ингибиторов киназы | |
| AU2013302473A1 (en) | Pyrrolopyrazoles as N-type calcium channel blockers | |
| AU2007298286A1 (en) | Pyrazolopyrimidine derivative | |
| JP2008505926A (ja) | 抗細菌剤 | |
| JP2008508359A (ja) | 抗菌剤 | |
| Ghorbani-Vaghei et al. | Poly (N-bromo-N-ethyl-benzene-1, 3-disulfonamide) and N, N, N′, N′-tetrabromobenzene-1, 3-disulfonamide as new efficient reagents for one-pot synthesis of furano and pyrano pyrimidinones (thiones) | |
| EP1893625A2 (en) | Methods for the preparation of 9-deazapurine derivatives | |
| Shishoo et al. | Studies on the synthesis and interconversion of isomeric triazolothienopyrimidines. Part III. Cyclization reactions of 2‐amino‐3‐(1H‐1, 2, 4‐triazol‐3‐yl) thiophenes | |
| Brukštus et al. | Synthesis of novel pyrimido [5, 4-f][1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazepines | |
| CN86104224A (zh) | 吡啶基取代的咪唑并[2，1-b]噻唑的制备方法 | |
| MXPA06006148A (en) | Process for the preparation of thiazolopyrimidines | |
| JP2545225B2 (ja) | 光学的活性ヒダントイン化合物 | |
| Vaskevich et al. | Reaction of substituted 2-allylthiopyrimidin-4 (3H)-ones with sulfenyl chlorides | |
| WO2025106949A1 (en) | Wrn inhibitors | |
| Heras et al. | Synthesis of Triazolo [1, 5‐a] triazin‐7‐one Derivatives and Highly Functionalized [1, 2, 4] Triazoles | |
| Zhai et al. | Synthetic strategies for piperazine derivatives | |
| Zaher | Synthesis of some new thiophene and thiopyrimidine compounds of expected anticancer activity and studying the augmenting effect of gamma radiation | |
| HK1121765A1 (en) | Anti-viral compounds |